QID 376457

Date Published: 2022-03-09

QID 376457: Mozilla Firefox ESR Multiple Vulnerabilities (MFSA2022-11)

Firefox is a free and open-source web browser developed for Windows, OS X, and Linux, with a mobile version for Android.

Mozilla Firefox ESR is prone to
CVE-2022-26383: Browser window spoof using fullscreen mode
CVE-2022-26384: iframe allow-scripts sandbox bypass
CVE-2022-26387: Time-of-check time-of-use bug when verifying add-on signatures
CVE-2022-26381: Use-after-free in text reflows
CVE-2022-26386: Temporary files downloaded to /tmp and accessible by other local users

Affected Products:
Prior to Firefox ESR 91.7

QID Detection Logic (Authenticated) :
This checks for vulnerable version of Firefox browser.


Note: The preceding description block is extracted directly from the security advisory. Using automation, we have attempted to clean and format it as much as possible without introducing additional issues.

Successful exploitation of this vulnerability could lead to a security breach or could affect integrity, availability, and confidentiality.

  • CVSS V3 rated as High - 6.2 severity.
  • CVSS V2 rated as Medium - 5.4 severity.
    • Solution
    Vendor has released fix to address these vulnerabilities. Refer to MFSA2022-11 or later
    Vendor References

    CVEs related to QID 376457

    CVE-2022-26381 | CVE-2022-26384 | CVE-2022-26386 | CVE-2022-26383 | CVE-2022-26387 |
    Software Advisories
    Advisory ID Software Component Link
    MFSA2022-11 URL Logo www.mozilla.org/en-US/security/advisories/mfsa2022-11/
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].